Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organovo Holdings, Inc. - Common Stock (NQ: ONVO )

1.270 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,777,136
Open 1.270
Bid (Size) 1.560 (33)
Ask (Size) 1.570 (37)
Prev. Close 1.270
Today's Range 1.270 - 1.270
52wk Range 0.3154 - 1.830
Shares Outstanding 8,716,953
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's going on in today's session
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Dow Surges 200 Points; Keurig Dr Pepper Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
+186.94%
+186.94%
1 Month
+252.78%
+252.78%
3 Month
+197.42%
+197.42%
6 Month
+105.47%
+105.47%
1 Year
+28.80%
+28.80%

More News

Read More
These stocks are the most active in today's session
Via Chartmill
Which stocks are experiencing notable movement on Tuesday?
Via Chartmill
Why Eli Lilly Stock Popped Today
Via The Motley Fool
Nasdaq Dips 1.5%; Home Depot Issues Weak Forecast
Via Benzinga
Traders are paying attention to the gapping stocks in Tuesday's session.
Via Chartmill
Why Organovo (ONVO) Stock Is Skyrocketing
Via Benzinga
What's going on in today's pre-market session
Via Chartmill
Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
From Organovo, Inc.
Via GlobeNewswire
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
From Organovo, Inc.
Via GlobeNewswire
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
From Organovo, Inc.
Via GlobeNewswire
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
From Organovo, Inc.
Via GlobeNewswire
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July
Via Benzinga
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
From Organovo, Inc.
Via GlobeNewswire
ONVO Stock Earnings: Organovo Holdings Beats EPS, Misses Revenue for Q4 2024
Via InvestorPlace
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
From Organovo, Inc.
Via GlobeNewswire
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
From Organovo, Inc.
Via GlobeNewswire
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
From Organovo, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Organovo Stock Is Up Today
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.